Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia Clinical Trial

Official title:
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy

Status Completed

Clinical Trial Summary

Primary Objective:

To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at high cardiovascular risk with non-HDL-C not adequately controlled with maximally tolerated statin therapy.

Secondary Objectives:

- To demonstrate whether alirocumab is superior in comparison with usual care in its effects on other lipid parameters (ie, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (Total -C), lipoprotein a (Lp[a]), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), triglyceride rich lipoproteins (TGRLs), apolipoprotein A-1 (Apo A-1), apolipoprotein C-III (Apo C-III), lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy (ie, LDL-C particle size and LDL, very low-density lipoprotein [VLDL], HDL, and intermediate-density lipoprotein [IDL] particle number).

- To assess changes in glycemic parameters with alirocumab vs. usual care treatment.

- To demonstrate the safety and tolerability of alirocumab.

- To evaluate treatment acceptance of alirocumab.

- To evaluate proprotein convertase subtilisin kexin type 9 (PCSK9) concentrations and antibody development.

- To demonstrate the superiority of alirocumab vs. fenofibrate on non-HDL-C and other lipid parameters (subgroup analysis).

Clinical Trial Description

The maximum study duration was approximately 9 months per participant, including a 6 month treatment period, a screening period of up to 3 weeks, and an 8 week safety observation period.

For the purpose of scientific communication, a first-step analysis (both efficacy and safety) was performed at the Week 24 cut-off date. A second-step analysis was performed once all participants had completed the study to include a final update of the safety analysis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02642159
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 4
Start date	March 15, 2016
Completion date	May 15, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00001154` - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting	`NCT06405880` - Pharmacist Case Finding and Intervention for Vascular Prevention Trial	N/A
Recruiting	`NCT02837367` - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People	N/A
Active, not recruiting	`NCT02600338` - Meta-analyses of the Effect of Legumes on Blood Pressure	N/A
Active, not recruiting	`NCT02223793` - Vascular Lifestyle-Intervention and Screening in Pharmacy	N/A
Completed	`NCT02163044` - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting	`NCT01972113` - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)	N/A
Recruiting	`NCT01705873` - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen	N/A
Completed	`NCT01764295` - Clinical Study for Patients With Hypertension Associated With Dyslipidemia	Phase 3
Terminated	`NCT01414166` - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)	Phase 3
Completed	`NCT01990391` - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities	N/A
Completed	`NCT01531062` - Effect of Nigella Sativa on Lipid Profiles in Elderly	Phase 2
Recruiting	`NCT01670968` - HIV Reverse Cholesterol Transport Study
Completed	`NCT00977288` - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)	Phase 2
Withdrawn	`NCT00664287` - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)	Phase 3
Completed	`NCT00768274` - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol	Phase 1/Phase 2
Completed	`NCT01285544` - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia	Phase 4
Completed	`NCT00300430` - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.	Phase 3
Completed	`NCT01483235` - Reduced Cardiac Rehabilitation Program	N/A
Completed	`NCT00309777` - Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.